ATE535807T1 - Gensignaturen - Google Patents

Gensignaturen

Info

Publication number
ATE535807T1
ATE535807T1 AT09728011T AT09728011T ATE535807T1 AT E535807 T1 ATE535807 T1 AT E535807T1 AT 09728011 T AT09728011 T AT 09728011T AT 09728011 T AT09728011 T AT 09728011T AT E535807 T1 ATE535807 T1 AT E535807T1
Authority
AT
Austria
Prior art keywords
obesity
molecules
tissue
correlating
identifying
Prior art date
Application number
AT09728011T
Other languages
English (en)
Inventor
Paul Holvoet
Nora Benhabiles
Benjamin Geeraert
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Application granted granted Critical
Publication of ATE535807T1 publication Critical patent/ATE535807T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Paper (AREA)
AT09728011T 2008-04-03 2009-04-02 Gensignaturen ATE535807T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7297108P 2008-04-03 2008-04-03
US12820508P 2008-05-19 2008-05-19
GBGB0809069.8A GB0809069D0 (en) 2008-05-19 2008-05-19 Gene signatures
US20070508P 2008-12-02 2008-12-02
PCT/BE2009/000022 WO2009121152A2 (en) 2008-04-03 2009-04-02 Gene signatures

Publications (1)

Publication Number Publication Date
ATE535807T1 true ATE535807T1 (de) 2011-12-15

Family

ID=39596133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09728011T ATE535807T1 (de) 2008-04-03 2009-04-02 Gensignaturen

Country Status (7)

Country Link
US (1) US20110053167A1 (de)
EP (1) EP2260301B9 (de)
AT (1) ATE535807T1 (de)
CA (1) CA2712331A1 (de)
DK (1) DK2260301T3 (de)
GB (1) GB0809069D0 (de)
WO (1) WO2009121152A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ586834A (en) 2008-01-18 2013-03-28 Methods of detecting signatures of disease or conditions in bodily fluids
EP2596349B1 (de) 2010-07-23 2017-12-13 President and Fellows of Harvard College Verfahren zum nachweis kardiovaskulärer erkrankungen oder leiden
US20120053073A1 (en) 2010-07-23 2012-03-01 President And Fellows Of Harvard College Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
WO2012072685A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
EP2653555A1 (de) * 2012-04-19 2013-10-23 Fundacion Centro Nacional De Investigaciones Cardiovasculares Carlos III (CINC) P38-MAPK-gamma und -delta zur Verwendung als Biomarker von Nichtalkoholischer Fettleberhepatitis
SG10201610537VA (en) 2012-06-15 2017-02-27 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
US9081854B2 (en) * 2012-07-06 2015-07-14 Hewlett-Packard Development Company, L.P. Multilabel classification by a hierarchy
EP2965086A4 (de) 2013-03-09 2017-02-08 Harry Stylli Verfahren zum nachweis von prostatakrebs
EP2965077B1 (de) 2013-03-09 2022-07-13 Harry Stylli Verfahren zur krebserkennung
WO2015081391A1 (en) * 2013-12-05 2015-06-11 Katholieke Universiteit Leuven Ku Leuven Research & Development Resistance to oxidative stress
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
EP3191846A4 (de) 2014-09-11 2018-06-13 Harry Stylli Verfahren zum nachweis von prostatakrebs
CN107208057A (zh) 2014-12-19 2017-09-26 Vrije布鲁塞尔大学 哺乳动物卵丘卵母细胞复合体的体外成熟
PL237595B1 (pl) * 2017-07-28 2021-05-04 Univ Medyczny W Bialymstoku Sposób oznaczania wrażliwości tkanek na insulinę oraz sposób identyfikacji insulinooporności i/lub określania predyspozycji do zaburzenia z nią związanego
TWI634902B (zh) * 2017-10-28 2018-09-11 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 Use of glucosamine peptide compounds for the treatment of abnormal liver metabolism
WO2020210487A1 (en) * 2019-04-12 2020-10-15 Cipher Genetics Inc. Systems and methods for nutrigenomics and nutrigenetic analysis
CN113208114B (zh) * 2020-07-14 2022-12-20 内蒙古蒙牛乳业（集团）股份有限公司 嗜热链球菌mn002在脂代谢调节中的用途及膳食补充剂
CN113355410A (zh) * 2021-07-09 2021-09-07 川北医学院附属医院 一种原发性痛风诊断标志物及应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP2192131A1 (de) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunglobuline ohne Leichtkette
EP0698097B1 (de) 1993-04-29 2001-08-16 Unilever N.V. Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
EP0739981A1 (de) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
EP0880598A4 (de) 1996-01-23 2005-02-23 Affymetrix Inc Verfahren zur analyse von nukleinsäure
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US7348181B2 (en) 1997-10-06 2008-03-25 Trustees Of Tufts College Self-encoding sensor with microspheres
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6262228B1 (en) * 1998-08-17 2001-07-17 Tularik Inc. IRAK3 polypeptides and methods
EP1144616B2 (de) 1999-01-19 2009-01-14 Unilever Plc Verfahren zur herstellung von antikörperfragmenten
MXPA01011915A (es) 1999-05-19 2003-09-04 Advanced Array Technologies S Metodo para la identificacion y/o la cuantificacion de un compuesto diana.
US7371516B1 (en) 1999-07-16 2008-05-13 Rosetta Inpharmatics Llc Methods for determining the specificity and sensitivity of oligonucleo tides for hybridization
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
EP1242460B1 (de) 1999-11-29 2006-10-18 Unilever Plc Immobilisierung von proteinen mit hilfe eines polypeptidsegments
EP1257664A4 (de) 2000-01-28 2006-04-05 Althea Technologies Inc Verfahren zur analyse der genexpression
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
JP2002262876A (ja) 2001-03-07 2002-09-17 Ngk Insulators Ltd 高感度な核酸のハイブリダイゼーション方法、及びその方法を用いた遺伝子解析方法
US7047141B2 (en) 2001-03-22 2006-05-16 Ge Healthcare Bio-Sciences Ab Ratio-based oligonucleotide probe selection
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US7189509B2 (en) 2001-08-16 2007-03-13 Zhifeng Shao Analysis of gene expression profiles using sequential hybridization
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
US7439346B2 (en) 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
WO2003091426A1 (en) 2001-10-12 2003-11-06 Spectral Genomics, Inc. Compilations of nucleic acids and arrays and methods of using them
US20040038322A1 (en) 2002-01-22 2004-02-26 Regents Of The University Of California Potentiation of cancer therapies by ZNF217 inhibition
US7221785B2 (en) 2002-05-21 2007-05-22 Agilent Technologies, Inc. Method and system for measuring a molecular array background signal from a continuous background region of specified size
US7031845B2 (en) 2002-07-19 2006-04-18 University Of Chicago Method for determining biological expression levels by linear programming
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
KR20050092029A (ko) 2003-01-10 2005-09-16 아블린쓰 엔.브이. 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
CA2463719A1 (en) 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
US7347921B2 (en) 2003-07-17 2008-03-25 Agilent Technologies, Inc. Apparatus and method for threading a biopolymer through a nanopore
US7353116B2 (en) 2003-07-31 2008-04-01 Agilent Technologies, Inc. Chemical array with test dependent signal reading or processing
GB0323238D0 (en) 2003-10-03 2003-11-05 Domantis Ltd Synthetic LG binding domains of protein L
WO2005052132A2 (en) 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
US7302348B2 (en) 2004-06-02 2007-11-27 Agilent Technologies, Inc. Method and system for quantifying and removing spatial-intensity trends in microarray data
US7323308B2 (en) 2004-09-03 2008-01-29 Affymetrix, Inc. Methods of genetic analysis of E. coli
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2006205900B8 (en) 2005-01-14 2012-04-05 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
WO2006083798A2 (en) 2005-01-31 2006-08-10 The Trustees Of Columbia University In The City Of New York Methods for treating obesity-related disorders by inhibiting myd88 and methods for identifying myd88 inhibitors
SI1888640T1 (sl) 2005-05-18 2012-07-31 Ablynx Nv Izboljšana nanotelesa proti faktorju nekroze tumorja alfa
EP1957537A2 (de) 2005-12-01 2008-08-20 Domantis Limited Kompetitive domänenantikörperformate, die an den interleukin-1-rezeptor vom typ 1 binden
BRPI0619225A2 (pt) 2005-12-01 2017-11-07 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória

Also Published As

Publication number Publication date
US20110053167A1 (en) 2011-03-03
GB0809069D0 (en) 2008-06-25
WO2009121152A3 (en) 2009-12-17
CA2712331A1 (en) 2009-10-08
EP2260301B1 (de) 2011-11-30
EP2260301B9 (de) 2012-07-11
WO2009121152A8 (en) 2011-12-29
WO2009121152A2 (en) 2009-10-08
EP2260301A2 (de) 2010-12-15
DK2260301T3 (da) 2012-03-12

Similar Documents

Publication Publication Date Title
ATE535807T1 (de) Gensignaturen
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
Huang et al. Circular RNA ciRS-7 triggers the migration and invasion of esophageal squamous cell carcinoma via miR-7/KLF4 and NF-κB signals
WO2008154333A3 (en) Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009070805A3 (en) Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
ATE534738T1 (de) Mir-126-regulierte gene und pfade als ziele für therapeutische interventionen
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2008085797A8 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2009044899A1 (ja) 細胞の増殖を制御する核酸
MX2020009811A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico.
WO2009140569A3 (en) Genetic markers for weight management and methods of use thereof
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2010048378A3 (en) Genetic markers for weight management and methods of use thereof
WO2011063098A3 (en) Genetic markers for weight management and methods of use thereof
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2011017516A3 (en) Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
MX2013004747A (es) Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson.
WO2008036718A3 (en) Mir-143 regulated genes and pathways as targets for therapeutic intervention
BR112015004653A2 (pt) método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas
MX2009008774A (es) La proteina secretada ccdc80 regula la diferenciacion de adipocito.
WO2009004632A3 (en) Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation